Opinion|Videos|August 13, 2024
The Evaluation of Dupilumab In Chronic Spontaneous Urticaria Treatment
A panel of experts discuss the clinical trials of dupilumab, the resultant data, and the response of the FDA when approval was requested.
Advertisement
Episodes in this series
Video content above is prompted by the following question:
- Dupilumab has been evaluated in phase 3 clinical trials in patients with chronic spontaneous urticaria (CSU). What did the data show and what was the FDA’s response to the requested approval?
- There is a Bruton tyrosine kinase (BTK) inhibitor under investigation in CSU. How does the BTK pathway differ from others that are targeted by CSU therapies?
a. BTK inhibitors are currently utilized in other disease states. What are the important clinical considerations with BTK inhibitors that clinicians should know?
b. How would the introduction of an oral therapy for CSU influence your treatment decisions?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer
2
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
3
More Potent and Tolerable, Azenosertib Advances as the Leading WEE1 Inhibitor
4
Clinicians Confront Fragmented Care and the Silent Burden of Undertreated Atopic Dermatitis
5